Search­ing for the next block­buster to fol­low Darza­lex, J&J finds a $150M an­ti-CD38 drug from part­ner Gen­mab

Now that J&J and Gen­mab have thrust Darza­lex on­to the reg­u­la­to­ry or­bit for first-line use in mul­ti­ple myelo­ma, the part­ners are lin­ing up a deal for a next-gen fol­low-on to the lead­ing CD38 drug.

Janssen — J&J’s biotech unit — has its eyes on Hexa­Body-CD38, a pre­clin­i­cal com­pound gen­er­at­ed on Gen­mab’s tech plat­form de­signed to make drugs more po­tent via hexa­m­er­iza­tion.

Gen­mab is foot­ing the bill on stud­ies in mul­ti­ple myelo­ma and dif­fuse large B-cell lym­phoma; once it com­pletes clin­i­cal proof of con­cept, Janssen has the op­tion to li­cense the drug for a $150 mil­lion ex­er­cise fee. There’s al­so $125 mil­lion worth of mile­stones in play.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER